Mills GB, Lu Y, Fang X, et al. The role of genetic abnormalities of PTEN and the phospatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Seminars in Oncol 2001; 28(suppl 16): 125–141.
Hu L, Zaloudek C, Mills G, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6(3): 880–886.
Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR). Pro-and anti-apoptotic. Cell Death Differ 2002; 9: 99–100.
Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increase sensitivity to cisplatin in vitro. Cancer Res 1995; 55(9): 1982–1988.
Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087–1092.
Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19(56): 6680–6686.
Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-barr virus-transformed B lymphocytes in vitro and in vivo: Potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97(8): 4285–4290.
Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98(18): 10314–10319.
Podsypanina K, Lee RT, Politis C, et al. Aninhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/− mice. Proc Natl Acad Sci USA 2001; 98(18): 10320–10325.
Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001; 7(6): 1758–1764.
Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res 2001; 61(8): 3373–3381.
Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacology 1998; 54: 815–824.
Castedo T, Roumier J, Blanco KF, et al. Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 2002; 21: 4070–4080.
Decaudin D, Hirsch T, Geley M, et al. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997; 57: 62–67.
Chan T-F, Carvalho J, Riles L, Zheng XSF. Achemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). Proc Natl Acad Sci USA 2000; 97(24): 13227–13232.
Hardwick JS, Kuruvilla FG, Tong JK, Shamji AF, Schreiber SL. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc Natl Acad Sci USA 1999; 96(26): 14866–14870 (http://www.pnas.org/cgi/content/full/96/26/14866/DC1).
Zangemeister-Wittke U, Leech SH, Olie RA, et al. Anovel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000; 6: 2547–2555.
Gautschi O, Tschopp S, Olie RA, et al. Activity of a novel bcl-2/ bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001; 93: 463–471.
Shinjyo T, Kuribara R, Inukai T, et al. Downregulation of bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol 2001; 21(3): 854–864.
Shinoura N, Yoshida Y, Nishimura M, et al. Expression level of bcl-2 determines anti-or proapoptotic function. Cancer Res 1999; 59: 4119–4128.
Torgler R, Jakob S, Ontsouka E, et al. Regulation of activation-induced Fas (CD95/Apo-1) ligand expression in T cells by the Cyclin B1/cdk1 complex. J Biol Chem 2004; Epub ahead of print June 23.
Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Medicine 2004; 10(6): 594–601.
Raymond E, Alexandre J, Faivre S, et al. Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer. J Clin Oncol 2004; 22(12): 2336–2347.